QN-247, formerly referred to as ALAN (Aptamer Linked Anti Nucleolin), is an aptamer-based investigational drug candidate currently under development and evaluation with the potential to treat a variety of different cancer types, including liquid and solid tumors. QN-247 is a DNA aptamer conjugated to a gold nanoparticle, which gives it increased potency and versatility. Preclinical studies in breast cancer with QN-247 showed significant cell inhibition activity. The broader versatility conferred by linking the aptamer to a gold nanoparticle includes such uses as enhanced radiation therapy, tumor imaging, and the delivery of other anti-cancer compounds directly to tumor cells.

Potential Additional Indications


QN-247RE, formerly referred to as ALAN-RE (Aptamer Linked Anti Nucleolin – Radiation Enhancement), is an aptamer-based investigational drug candidate currently under development and evaluation to be used in combination with radiation therapy to treat virtually any type of cancer. The gold nanoparticle component of this drug candidate enhances radiation therapy by “magnifying” the effects of radiation on the targeted tumor cells. Because of this beneficial effect, lower doses of radiation can be used, resulting in fewer side effects for patients undergoing radiation therapy for their cancers.

QN-247CE, formerly referred to as ALAN-CE (Aptamer Linked Anti Nucleolin – Contrast Enhancement), is an aptamer-based investigational drug candidate currently under development and evaluation to be used in combination with imaging technologies to provide higher resolution images of solid tumors and tumor cells. Special imaging dyes can be attached to the gold nanoparticle compound, which are then easily detected in tumor cells, providing higher resolution images to radiologists and oncologists.